Home › Trials › NCT07115940
Clinical trial Recruiting at 6 sites Interventional Ages 18 to 85

Thrombectomy plus medical care versus medical care alone for large-vessel ischemic stroke 24–72 hours after last known well

Official title: Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well - SELECT LATE Trial

Run by University Hospitals Cleveland Medical Center · NCT07115940 · Data updated 2026-11-12

This will see if adding endovascular thrombectomy to usual medical care helps adults with a large-vessel ischemic stroke who arrive 24–72 hours after they were last known to be well.

More Acute Ischemic Stroke trials

Quick facts

Study typeInterventional
Ages18 Years to 85 Years
SexAll
Enrollment408 (estimated)
SponsorUniversity Hospitals Cleveland Medical Center
Academic / other
Locations6 sites (Chicago, Illinois and 5 other locations)
StatusRecruiting
StartedApril 13, 2026
Main results expectedNovember 1, 2029
Study endsDecember 1, 2029
Registry record updatedJuly 6, 2026
Trial IDNCT07115940 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–85 with an acute ischemic stroke due to an ICA or MCA-M1 large-vessel occlusion who present 24–72 hours after last known well, have NIHSS ≥6, pre-stroke mRS 0–1, and meet imaging criteria (ASPECTS 3–10 and ischemic core ≤150 mL) are the ideal candidates.

Probably not a fit

Patients with very large ischemic cores (>150 mL), posterior-circulation occlusions, significant pre-stroke disability (mRS >1), presentation outside the 24–72 hour window, or other exclusion criteria (for example platelet count <100,000/μL or concurrent participation in another interventional study) are unlikely to benefit from enrollment.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

SELECT LATE randomly assigns eligible adults with an anterior-circulation large-vessel occlusion who present 24–72 hours after last known well to receive endovascular thrombectomy plus standard medical care or standard medical care alone, with treating centers and outcome assessors blinded to assignment when possible. Key imaging eligibility includes non-contrast CT ASPECTS 3–10 and an ischemic core volume ≤150 mL, and patients must have NIHSS ≥6 and pre-stroke mRS 0–1. The primary outcome is a shift in modified Rankin Scale scores at 90 days (±15 days); secondary outcomes include functional independence, utility-weighted mRS, quality of life measures, and safety endpoints such as mortality and severe disability. Assessments occur at baseline, 24 hours, discharge, 90 days, and one year.

Why it matters

Potential benefit: If successful, adding thrombectomy in this later time window could increase the chances of better functional recovery and independence at 90 days for patients with late-presenting large-vessel occlusions.

How similar studies have gone: Previous randomized trials (DAWN and DEFUSE 3) demonstrated benefit for thrombectomy out to 24 hours, but randomized evidence for the 24–72 hour window is limited, so this approach is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

General Inclusion Criteria:

* Adults (18-85\* years) with the final diagnosis of an acute ischemic stroke$
* NIHSS ≥ 6
* Time from last-known-well to randomization \>24 - 72 hours
* Pre-stroke modified Rankin Scale score of 0-1
* Eligible for thrombectomy and medical management
* Signed Informed Consent obtained
* Subject willing to comply with the protocol follow-up requirements
* Anticipated life expectancy of at least 3 months \*Inclusive of both 18 and 85 years of age (i.e. up to 86th birthdate). $Subacute presentation - In-hospital stroke admissions with fluctuating clinical symptoms for patients who presented to EVT centers within 24 hours of when they were last known well will not be eligible for the trial.

General Exclusion Criteria

* Current participation in another investigational interventional drug or device study.
* Baseline Platelet count \<100,000/μl

Imaging Inclusion Criteria

* Proven large vessel occlusion in ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions), as determined by MR Angiography (MRA) or CT Angiography (CTA)
* CT ASPECTS 3-10
* CT Perfusion ischemic core (rCBF \<30%)# volume ≤150 ml OR MR Diffusion ischemic core (ADC \<620x10-6 mm2/s)# volume ≤150ml #If the perfusion software at enrollment center uses another threshold/measure to define ischemic core, please use that measure to assess ischemic core criteria.

Imaging Exclusion Criteria

* Evidence of intracranial tumor (except small meningioma \<3cm without signs of edema or inflammation), acute intracranial hemorrhage, or arteriovenous malformation
* Significant mass effect, defined as midline shift (\>3mm) using foramen of monroe (anterior margin of third ventricle) as the marker for midline instead of septum pellucidum AND/OR Effacement of sulci in contralateral hemisphere
* Evidence of internal carotid artery dissection that is flow limiting or aortic dissection
* Intracranial stent implanted in the same vascular territory that precludes the safe deployment/removal of the neurothrombectomy device
* Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion).
* Any signs of established infarct, demarcating hypodensity and area of cerebral edema on non-contrast CT
* CT ASPECTS 0-2
* CT Perfusion ischemic core (rCBF \<30%)# volume \>150 ml OR MR Diffusion ischemic core (ADC \<620x10-6 mm2/s)# volume \>150ml #If the perfusion software at enrollment center uses another threshold/measure to define ischemic core, please use that measure to assess ischemic core criteria.

Where it's running

  • University of Chicago
    Chicago, Illinois, United States     Recruiting
  • The University of Kansas Health System
    Kansas City, Kansas, United States     Recruiting
  • Washington University School of Medicine
    St Louis, Missouri, United States     Recruiting
  • Rhode Island Hospital
    Providence, Rhode Island, United States     Recruiting
  • Baylor University Medical Center
    Dallas, Texas, United States     Recruiting
  • West Virginia University
    Morgantown, West Virginia, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Acute Ischemic Stroke 172University Hospitals Cleveland Medical Center 43
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.